Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 6/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.40 |
| ▸ | CDK2 | P24941 | 5/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.40 |
| ▸ | PRKAB2 | O43741 | 3/20 | 0.39 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.39 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.39 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.39 |
| ▸ | PRKAG3 | Q9UGI9 | 3/20 | 0.39 |
| ▸ | PRKAG2 | Q9UGJ0 | 3/20 | 0.39 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.39 |
| ▸ | FLT1 | P17948 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15031456 | 1.00 | CHEK1 (0.40) | CHEK1CCNA2CDK2CCNA1PRKAB2 | |
| SCHEMBL15007075 | 1.00 | CHEK1 (0.40) | CHEK1CCNA2CDK2CCNA1PRKAB2 | |
| SCHEMBL15007196 | 0.91 | KDM4E (0.39) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL15031447 | 0.91 | KDM4E (0.39) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL15007197 | 0.91 | KDM4E (0.39) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL15007182 | 0.87 | CHEK1 (0.43) | CHEK1CCNA2CDK2CCNA1KDR | |
| SCHEMBL15031455 | 0.87 | CHEK1 (0.43) | CHEK1CCNA2CDK2CCNA1KDR | |
| SCHEMBL15007183 | 0.87 | CHEK1 (0.43) | CHEK1CCNA2CDK2CCNA1KDR | |
| SCHEMBL15007203 | 0.87 | CHEK1 (0.43) | CHEK1CCNA2CDK2CCNA1KDM4E | |
| SCHEMBL15007204 | 0.87 | CHEK1 (0.43) | CHEK1CCNA2CDK2CCNA1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2608669-B1 | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME (US) | 2016-06-22 | — | — | EP | claimed |
| US-8883801-B2 | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-11-11 | — | — | US | claimed |
| US-20130150362-A1 | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-06-13 | — | — | US | claimed |
| EP-2608669-B1 | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME (US) | 2016-06-22 | — | — | EP | disclosed |
| US-8883801-B2 | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20130150362-A1 | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150362-A1 | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RPS6KA5, PAK5 | CHEK1 591/4885CCNA2 2405/4885CDK2 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.